Investment in ADC Biotechnology
3 November 2017
Share
Completion Date: 09/2017
Target: ADC Biotechnology
Deal Value: Undisclosed
Details: HMT LLP, led by partner Paul Read advised Maven
Capital Partners on its investment in anti-cancer drugs
manufacturer ADC Biotechnology
Funding: Maven Capital Partners
Financial Due Diligence: HMT